In a patient with acute liver failure due to suspected poisoning, should plasmapheresis be initiated as a bridge to liver transplantation?

Plasmapheresis in Acute Liver Failure from Suspected Poisoning: Not Recommended as Standard Practice

Plasmapheresis should NOT be routinely initiated as a bridge to liver transplantation in acute liver failure due to suspected poisoning—instead, focus on specific antidotes (N-acetylcysteine for acetaminophen, penicillin G/silymarin for mushrooms) and early transplant center contact, reserving plasmapheresis only for specific poisonings like yellow phosphorus when transplantation is unavailable.

Primary Management Algorithm for Poisoning-Related ALF

Immediate Actions (First 4 Hours)

1. Identify the toxin immediately through history, serum acetaminophen levels, and toxicology screening 1

2. Start N-acetylcysteine empirically in ALL cases of ALF where poisoning is suspected, regardless of the specific toxin 1:

   • Loading dose: 150 mg/kg IV over 15 minutes
   • Maintenance: 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours
   • Continue even if acetaminophen levels are low or undetectable 2

3. Contact transplant center immediately for all patients with prothrombin time <50% 1

4. Give activated charcoal (1 g/kg) if ingestion occurred within 3-4 hours, administered just BEFORE starting N-acetylcysteine 2

Toxin-Specific Antidotes (Not Plasmapheresis)

For Acetaminophen (most common cause):

• N-acetylcysteine is the definitive treatment with proven mortality reduction (37% vs 63% without treatment) 1
• Improves transplant-free survival even in non-acetaminophen ALF 1

For Mushroom Poisoning (Amanita phalloides):

• Penicillin G: 300,000-1 million units/kg/day IV 2
• Silymarin: 30-40 mg/kg/day IV or oral for 3-4 days 2
• List for transplantation immediately—this is often the only lifesaving option 2

For Other Drug/Toxin Hepatotoxicity:

• Discontinue ALL non-essential medications 2
• N-acetylcysteine may still provide benefit 1

When Plasmapheresis Has Limited Evidence

Critical Limitations from Guidelines

The major ALF guidelines (AASLD 2005 2, AGA 2017 3, SCCM 2023 4) do not recommend plasmapheresis as standard therapy. The 2020 French ICU guidelines 1 and 2023 SCCM guidelines 4 found insufficient evidence for extracorporeal liver support systems, noting only a non-significant trend toward mortality reduction.

Specific Context Where Plasmapheresis May Be Considered

Yellow phosphorus poisoning ONLY when liver transplantation is not available 5, 6, 7:

• This is a geographically specific problem (Asia, parts of Americas)
• Studies show 70-79% survival with plasmapheresis 5, 7
• Outcome depends on: quantity consumed (<10 gm better), time to hospital admission (<4 days better), and time to start plasmapheresis (<5 days better) 5
• Requires 3-4 sessions on average 5

Wilson's disease with acute liver failure 8:

• Plasmapheresis/hemofiltration may protect kidneys from copper-mediated damage
• Used only as temporary bridge until transplantation
• Transplantation remains the definitive treatment

Why Plasmapheresis Is Not Standard Practice

Evidence Quality Issues

The 2023 SCCM guidelines 4 reviewed 24 RCTs (n=1,778) and found:

• Only 3.1% absolute mortality reduction in acute liver disease (not statistically significant)
• 11.5% reduction in acute-on-chronic disease (also not significant)
• High cost, resource-intensive, significant potential toxicities
• Adverse events include hypotension (11.6%) and allergic reactions (4.7%) 7

What Actually Improves Mortality

N-acetylcysteine has proven benefit 1, 3:

• Strong recommendation (GRADE 1+) for acetaminophen-related ALF 3
• Meta-analysis shows 88% reduction in mortality (RR 0.12,95% CI 0.04-0.38) 1
• Improves transplant-free survival (64% vs 26%) and post-transplant survival (85.7% vs 71.4%) in non-acetaminophen ALF 1

Common Pitfalls to Avoid

1. Waiting for acetaminophen levels before starting N-acetylcysteine—levels may be undetectable if ingestion was remote or occurred over multiple days 2, 1

2. Delaying transplant center contact—should occur within hours of diagnosis, not after failed medical management 2, 1

3. Using plasmapheresis instead of specific antidotes—this wastes critical time when proven therapies exist 2

4. Routine coagulation correction—restrict clotting factors unless active bleeding 1

5. Administering lactulose or rifaximin—these do NOT improve outcomes in ALF 1

Bottom Line for Clinical Practice

For suspected poisoning causing ALF, the evidence-based approach is:

1. Start N-acetylcysteine immediately (works for multiple etiologies)
2. Identify specific toxin and add targeted antidote
3. Contact transplant center within hours
4. Reserve plasmapheresis only for yellow phosphorus poisoning when transplant unavailable, or Wilson's disease as temporary bridge

Plasmapheresis lacks robust evidence for routine use and should not delay proven interventions or transplant evaluation 3, 4.